Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Global Cord Blood (OTCPK:CORBF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Global Cord Blood's Enterprise Value for the quarter that ended in Mar. 2022 was $-581.0 Mil.
Global Cord Blood's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $95.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Cord Blood EV-to-EBIT Related Terms
Global Cord Blood EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Global Cord Blood's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Global Cord Blood's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Cord Blood EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Global Cord Blood's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Global Cord Blood's EV-to-EBIT falls into.
Global Cord Blood's current Enterprise Value is $-721.7 Mil.
Global Cord Blood's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $95.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Cord Blood (CORBF) has a EV-to-EBIT of -7.59 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Global Cord Blood and its competitors.
Is Global Cord Blood's EV-to-EBIT too high?
Global Cord Blood's current EV-to-EBIT is -7.59. Overall, Global Cord Blood has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Global Cord Blood's EV-to-EBIT compare to PRE and LMDX?
Global Cord Blood's EV-to-EBIT of -7.59 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EV-to-EBIT is 23.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.07, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Global Cord Blood and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Global Cord Blood's current EV-to-EBIT is -7.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Cord Blood stock overvalued right now?
Global Cord Blood (CORBF) has a current EV-to-EBIT of -7.59. The current EV-to-EBIT is -7.59. Global Cord Blood's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Global Cord Blood (CORBF), the current EV-to-EBIT is -7.59 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants. The company generates all of its revenues by providing subscribers with processing services, which consist of the testing and processing of cord blood units, and storage services, which consist of the storage of cord blood units in its facilities.
12GF Score
Get the complete analysis for CORBF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORBF has been successfully added to your 
